SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Boxlight Corp. is a technological company, which engages in developing, selling, and providing interactive classroom solutions for the global education market. It also designs, manufactures, and distributes interactive projectors, flat panel displays, touch projectors, touch boards, and MimioTeach through the Boxlight Group and Genesis brands. The company was founded by Herbert Myers and Sloan Myers in 1985 and is headquartered in Duluth, GA.

Boxlight Corporation - Ordinary Shares - Class A

Boxlight Corp

BOXL is trending due to a reported breakout potentially fueled by news of shipping Google EDLA-certified interactive displays. Community discussions revolve around short squeeze potential and high volatility. Some traders point to the company's history of dilution as a reason for caution, while others express optimism for a continued run.

AgriFORCE Growing Systems Ltd. is an agriculture technology company, which engages in the development and utilization of intellectual property (IP) assets for improvement. Its solutions include consulting, air and surface sterilization, and other projects. The company was founded on December 22, 2017 and is headquartered in Vancouver, Canada.

AgriFORCE Growing Systems ltd

AgriFORCE is trending due to news of a potential $550 million fundraising plan led by Anthony Scaramucci to acquire AVAX tokens, with the company potentially shifting its focus to crypto. The community is discussing the low float, potential for a squeeze, and comparing it to other recent runners. Some traders are also noting the company's planned name change to AVAX One.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to a Wedbush price target increase, driven by confidence in its nuclear growth strategy amid the AI revolution and potential policy tailwinds. Community members are debating the valuation, short interest, and the sustainability of the recent parabolic move, with some citing insider selling and potential dilution as concerns. The stock is also garnering attention as it broke ground on its first Aurora powerhouse in Idaho.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to its acquisition of Metsera, a company focused on obesity drugs, for up to $7.3 billion, a move that signals PFE's renewed interest in the weight-loss market. Community discussion revolves around the potential impact of this acquisition on competitors like Viking Therapeutics and the broader implications for Pfizer's pipeline and future growth strategy within the competitive pharmaceutical landscape.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

BINI is trending due to a planned reverse stock split, its ninth since 2022, leading to concerns about value dilution and potential delisting. The community expresses frustration and accuses the company of being a scam, with many sharing stories of significant losses and criticizing management. Discussions also include the broader context of reverse splits and regulatory oversight.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending as traders discuss the impact of the company receiving FDA 510(k) clearance for its RNA sequencing diagnostic device, Tempus xR IVD. Community members are highlighting the potential for a short squeeze and anticipating a climb to new all-time highs, with some suggesting a target price of $100. Bullish sentiment is fueled by the clearance's potential to support drug development programs and the company's growing presence in the AI-driven healthcare sector.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to news of Mike Alfred joining the board, sparking excitement about his potential to accelerate growth and shape the company's strategy in digital assets and AI. The community is actively discussing how this appointment could enhance Bakkt's position in the fintech and crypto space. Bullish sentiment is also fueled by speculation around potential acquisitions and the company's moves in the crypto sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid a critique amplified by Martin Shkreli questioning its technology's viability, sparking debate about its quantum advantage claims and long-term prospects. The community is weighing the criticism against positive developments like institutional buying and potential government support for quantum computing, resulting in volatile trading and discussions around short squeezes and future catalysts.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific is trending due to discussions around a proposed merger with Strive, Inc. ($ASST) in an all-stock transaction that values SMLR at a significant premium, and community members are weighing the potential benefits and risks. Some traders are focusing on a lawsuit the company is facing, while others are eyeing the Bitcoin treasury aspect of the deal, especially as it relates to the valuation of both companies.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

MBX Biosciences is trending due to positive Phase 2 trial results for its hypoparathyroidism drug, canvuparatide, showing a significant responder rate and prompting discussions of potential Phase 3 advancement. The community is actively discussing the possibility of a short squeeze and the stock's potential to break past key resistance levels. This positive data and potential advancement come as the company is also working on an obesity candidate, contributing to overall investor excitement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet

The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVE Research Report), Passage Bio...

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 26 for the...

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven...

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Passage Bio Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$2.81	--	--	N/A
Q2 '25	-$4.04	-$2.96	26.73%	BEAT
Q1 '25	-$0.23	-$5.00	-2073.91%	MISSED
Q4 '24	-$0.22	-$0.20	11.11%	BEAT
Q3 '24	-$0.23	-$0.31	-33.75%	MISSED

PASG
Passage Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest PASG News

PASG Passage Bio Inc